
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6420388/publications.pdf Version: 2024-02-01



Shdiini S Rayi

#	Article	IF	CITATIONS
1	Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. Value in Health, 2022, 25, 230-237.	0.1	3
2	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid, 2022, 32, 273-282.	2.4	30
3	The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. Journal of Psychosocial Oncology, 2021, 39, 285-293.	0.6	18
4	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 30-37.	0.8	239
5	Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma. Future Oncology, 2021, 17, 3037-3050.	1.1	7
6	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 106, 564-570.	0.4	51
7	First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncology, 2020, 16, 4341-4345.	1.1	10
8	Letting the GENIE Out of Its Bottle: Examining the Potential of Real-World Clinicogenomic Data. Cancer Discovery, 2020, 10, 490-491.	7.7	2
9	Using electronic health record data to identify comparator populations for comparative effectiveness research. Journal of Medical Economics, 2020, 23, 1618-1622.	1.0	6
10	Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2020, 25, e1753-e1762.	1.9	6
11	OP520 Evaluating Long-Term Survival From Clinical Trials: Does Real-World Evidence Change the Paradigm?. International Journal of Technology Assessment in Health Care, 2020, 36, 12-12.	0.2	1
12	Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 1209.	3.8	20
13	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. Cancer, 2019, 125, 2984-2990.	2.0	4
14	Automating Treatment Summary Development Using Electronic Billing Information: A Pilot Study of Survivors of Head and Neck Cancer. Journal of Oncology Practice, 2019, 15, e84-e90.	2.5	0
15	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1417-1428.	1.8	165
16	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
17	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 360, k793.	2.4	438
18	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. Journal of Oncology Practice, 2018, 14, 72-76.	2.5	8

#	Article	IF	CITATIONS
19	Incorporating Multiple Perspectives Into the Development of an Electronic Survivorship Platform for Head and Neck Cancer. JCO Clinical Cancer Informatics, 2018, 2, 1-15.	1.0	13
20	Longâ€ŧerm quality of life in older patients with HPVâ€related oropharyngeal cancer. Head and Neck, 2018, 40, 2321-2328.	0.9	6
21	Patient Reflections on Decision Making for Laryngeal Cancer Treatment. Otolaryngology - Head and Neck Surgery, 2017, 156, 299-304.	1.1	47
22	Overuse of Health Care Services in the Management of Cancer. Medical Care, 2017, 55, 723-733.	1.1	39
23	Quality of Cancer Surveillance Clinical Practice Guidelines. JAMA Internal Medicine, 2017, 177, 701.	2.6	20
24	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensityâ€modulated radiotherapy era. Cancer, 2017, 123, 1345-1353.	2.0	20
25	Consider Quality of Life to Improve Quality of Cancer Guidelines—Reply. JAMA Internal Medicine, 2017, 177, 1538.	2.6	Ο
26	Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1140-1163.	2.3	81
27	Association of Number of Dissected Lymph Nodes With Survival in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma Patients Undergoing Primary Surgery. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1049.	1.2	15
28	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodineâ€refractory thyroid cancer. Cancer, 2017, 123, 4114-4121.	2.0	59
29	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	3.4	191
30	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
31	Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. European Endocrinology, 2017, 13, 26.	0.8	2
32	Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. Head and Neck, 2016, 38, E165-71.	0.9	26
33	A review of weight loss and sarcopenia in patients with head and neck cancer treated with chemoradiation. Cancers of the Head & Neck, 2016, 1, 9.	6.2	25
34	Moving survivorship care plans forward: focus on care coordination. Cancer Medicine, 2016, 5, 1717-1722.	1.3	23
35	Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncology, 2016, 62, 147-148.	0.8	32
36	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. Cancers of the Head & Neck, 2016, 1, 4.	6.2	19

#	Article	IF	CITATIONS
37	Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensityâ€modulated ra therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E566-70.	diation 0.9	35
38	Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer, 2016, 122, 1523-1532.	2.0	128
39	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus–Related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics. 2016. 96. 9-17.	0.4	121
40	Evaluating the Potential Role of PET/CT in the Posttreatment Surveillance of Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 252-254.	2.3	4
41	Treatmentâ€related toxicities in older adults with head and neck cancer: A populationâ€based analysis. Cancer, 2015, 121, 2083-2089.	2.0	54
42	Reply to B. O'Sullivan et al. Journal of Clinical Oncology, 2015, 33, 1710-1710.	0.8	6
43	Value Considerations in the Treatment of Head and Neck Cancer: Radiation, Chemotherapy, and Supportive Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e296-e303.	1.8	9
44	Treatment complications and survival in advanced laryngeal cancer: A population-based analysis. Laryngoscope, 2014, 124, 2707-2713.	1.1	46
45	Survivorship care plans: Is there buyâ€in from community oncology providers?. Cancer, 2014, 120, 722-730.	2.0	59
46	Causes of death in longâ€ŧerm survivors of head and neck cancer. Cancer, 2014, 120, 1507-1513.	2.0	175
47	Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information. Journal of Oncology Practice, 2014, 10, e277-e282.	2.5	25
48	Synchronous cancers in patients with head and neck cancer. Cancer, 2013, 119, 1832-1837.	2.0	98
49	Solid Tumor Second Primary Neoplasms: Who Is at Risk, What Can We Do?. Seminars in Oncology, 2013, 40, 676-689.	0.8	60
50	Sharing a diagnosis of HPV-related head and neck cancer: The emotions, the confusion, and what patients want to know. Head and Neck, 2013, 35, 1534-1541.	0.9	52
51	Hemorrhagic Pseudoaneurysm in a Patient Receiving Aflibercept for Metastatic Thyroid Cancer. Thyroid, 2012, 22, 552-555.	2.4	4
52	Ten Years of Progress in Head and Neck Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 806-810.	2.3	44
53	Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Research, 2011, 31, 249-53.	0.5	66
54	State-of-the-art Issues in Hodgkin's Lymphoma Survivorship. Current Oncology Reports, 2010, 12, 366-373.	1.8	24

#	Article	IF	CITATIONS
55	The Future of Mammography: Radiology Residents' Experiences, Attitudes, and Opinions. American Journal of Roentgenology, 2010, 194, 1680-1686.	1.0	8
56	Breast Imaging Fellowships in the United States: Who, What, and Where?. American Journal of Roentgenology, 2009, 192, 403-407.	1.0	8
57	Acute Limbic Encephalitis: Diagnostic and Management Implications. Australian and New Zealand Journal of Psychiatry, 2008, 42, 166-169.	1.3	1